0001193125-26-177292.txt : 20260424 0001193125-26-177292.hdr.sgml : 20260424 20260424161505 ACCESSION NUMBER: 0001193125-26-177292 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20260415 FILED AS OF DATE: 20260424 DATE AS OF CHANGE: 20260424 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Newcomb Jessica CENTRAL INDEX KEY: 0002130408 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39485 FILM NUMBER: 26894141 MAIL ADDRESS: STREET 1: C/O TANGO THERAPEUTICS, INC. STREET 2: 201 BROOKLINE AVE., SUITE 901 CITY: BOSTON STATE: MA ZIP: 02215 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tango Therapeutics, Inc. CENTRAL INDEX KEY: 0001819133 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 901 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (857) 320-4900 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 901 CITY: BOSTON STATE: MA ZIP: 02215 FORMER COMPANY: FORMER CONFORMED NAME: BCTG Acquisition Corp. DATE OF NAME CHANGE: 20200723 3 1 ownership.xml 3 X0607 3 2026-04-15 0 0001819133 Tango Therapeutics, Inc. TNGX 0002130408 Newcomb Jessica false C/O TANGO THERAPEUTICS, INC. 201 BROOKLINE AVE., SUITE 901 BOSTON MA 02215 false true false false Principal Accounting Officer Common Stock 67321 D Stock Option (Right to Buy) 4.26 2032-09-01 Common Stock 130000 D Stock Option (Right to Buy) 5.20 2033-03-01 Common Stock 31418 D Stock Option (Right to Buy) 2.67 2033-06-01 Common Stock 2000 D Stock Option (Right to Buy) 12.28 2034-02-01 Common Stock 74295 D Stock Option (Right to Buy) 3.13 2035-01-02 Common Stock 10000 D Stock Option (Right to Buy) 2.91 2035-02-03 Common Stock 126188 D Stock Option (Right to Buy) 8.93 2036-01-02 Common Stock 1000 D Stock Option (Right to Buy) 11.94 2036-02-02 Common Stock 153094 D The amount reported in Column 2 includes 43,666 unvested restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. This option vests and becomes exercisable over a four-year period, at a rate of 25% on August 1, 2023, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option vests and becomes exercisable over a four-year period, at a rate of 25% on January 1, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option is fully vested and exercisable. This option vests and becomes exercisable over a four-year period, at a rate of 25% on January 1, 2025, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option vests and becomes exercisable over a four-year period, with the option shares vesting in 48 equal monthly installments beginning on January 14, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option vests and becomes exercisable over a four-year period, at a rate of 25% on January 1, 2026, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option vests and becomes exercisable over a one-year period, with the option shares vesting in 12 equal monthly installments beginning on November 23, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. This option vests and becomes exercisable over a four-year period, at a rate of 25% on January 1, 2027, with the remaining option shares vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Exhibit 24: Power of Attorney /s/ Julie Fogarty, as attorney-in-fact 2026-04-24 EX-24 2 tngx-ex24.htm EX-24 EX-24

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Julie Fogarty and Matthew Gall, signing singly, the undersigned’s true and lawful attorney-in-fact to:

(1)
execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of Tango Therapeutics, Inc. (the “Company”), (i) Form ID, including any attached documents, to effect the assignment of codes to the undersigned to be used in the transmission of information to the United States Securities and Exchange Commission using the EDGAR System, (ii) Forms 3, 4 and 5, (iii) Schedule 13D, (iv) Schedule 13G and (v) amendments of each thereof, in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
(2)
do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D. Schedule 13G or any amendments thereto and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
(3)
take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted, the undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees to indemnify the attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorney-in-fact.

 

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. This Power of Attorney may be filed with the United States Securities and Exchange Commission as a confirming statement of the authority granted herein. This Power of Attorney supersedes any prior power of attorney in connection with the undersigned’s capacity as an officer and/or director of the Company, this Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an executive officer of the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 24th day of April, 2026.

 

/s/ Jessica Newcomb

 

Name: Jessica Newcomb